PURE Bioscience, Inc.
PURE
$0.0688
$0.013825.09%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 556.00K | 474.00K | 441.00K | 326.00K | 722.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 556.00K | 474.00K | 441.00K | 326.00K | 722.00K |
| Cost of Revenue | 231.00K | 199.00K | 183.00K | 149.00K | 280.00K |
| Gross Profit | 325.00K | 275.00K | 258.00K | 177.00K | 442.00K |
| SG&A Expenses | 881.00K | 845.00K | 998.00K | 1.07M | 1.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.18M | 1.11M | 1.26M | 1.29M | 1.43M |
| Operating Income | -627.00K | -639.00K | -817.00K | -964.00K | -711.00K |
| Income Before Tax | -689.00K | -756.00K | -857.00K | -1.00M | -735.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -689.00K | -756.00K | -857.00K | -1.00M | -735.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -689.00K | -756.00K | -857.00K | -1.00M | -735.00K |
| EBIT | -627.00K | -639.00K | -817.00K | -964.00K | -711.00K |
| EBITDA | -590.00K | -601.00K | -781.00K | -927.00K | -674.00K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 111.86M | 111.86M | 111.86M | 111.86M | 111.86M |
| Average Diluted Shares Outstanding | 111.86M | 111.86M | 111.86M | 111.86M | 111.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
